LabCompass

Greg Andrew Durm

Medicine · Indiana University

OpenAlex ORCID
Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Publications

84

Citations

874

Est. group size

—

Recurring co-author estimate

Active years

13

Publishing since 2014

Research summary
AI-generated

Greg Andrew Durm conducts clinical cancer research focused on treatments for lung cancer, particularly non-small cell lung cancer (NSCLC). Much of the work involves clinical trials testing immunotherapy drugs (which help the immune system attack tumors) and targeted therapies, often in combination with chemotherapy. This research also contributes to national treatment guidelines that help doctors decide how to treat patients.

Non-small cell lung cancer therapyCancer immunotherapy and checkpoint inhibitorsClinical trials of combination treatmentsTargeted therapies for solid tumorsCancer treatment guidelines

Publication activity has been steady over the last decade, with roughly 5 to 12 papers per year and no clear long-term increase or decline.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence
Publications per year over the last 10 years — averaging 6.6/year recently
2017: 6 publications172018: 6 publications182019: 11 publications192020: 11 publications202021: 12 publications12212022: 5 publications222023: 5 publications232024: 11 publications242025: 10 publications252026: 2 publications26
Recent publications
Publishes in
  • Journal of Clinical Oncology×33
  • Journal of Thoracic Oncology×13
  • International Journal of Radiation Oncology*Biology*Physics×6
  • Annals of Oncology×5
  • Clinical Lung Cancer×4

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile